The HIV has signed off on Merck’s daily pill Idvynso for the treatment of virologically suppressed HIV-1 in adults. The drug will hit U.S. shelves after May 11, according to a Tuesday news release.

The approval “could position Merck as a more meaningful competitor in HIV,” BMO Capital Markets told investors on Tuesday afternoon. The pharma “aims to market Idvynso as the new HIV anchor treatment.”

Indeed, Merck noted that Idvynso is intended “to replace the current antiretroviral regimen in those who are virologically suppressed,” particularly patients with no history of treatment failure or known resistance to doravirine.